What is Acadia Pharmaceuticals's market cap?

Acadia Pharmaceuticals (ACAD) has a market capitalization of $4.3B and trades on NASDAQ.

What is Acadia Pharmaceuticals's revenue and profitability?

Acadia Pharmaceuticals generated $1.1B in trailing twelve-month revenue with net income of $375.7M, representing a net margin of 34.3%. Gross margin stands at 91.5%, with free cash flow of $186.7M. These figures are based on the Q1 2026 filing.

Who are Acadia Pharmaceuticals's competitors?

Acadia Pharmaceuticals's key competitors include Neurocrine Biosciences, Biogen, Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Where is Acadia Pharmaceuticals headquartered?

Acadia Pharmaceuticals is headquartered in United States of America and employs approximately 610 people. It has been publicly traded since 2004.

Acadia Pharmaceuticals

ACAD

Acadia Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological and rare diseases.

Market cap

$4.35B+10.4%

Revenue$1.1B+9.9%

Net income$375.7M+64.1%

Free cash flow$186.7M+13.4%

EPS (diluted)$2.21+61.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$268.1MMiss by $12.2M EPS$0.02Miss by $0.02

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$295.5M

EPS estimate$0.06

Financials

Q1 2026

Income statement

See full

Revenue$268.1M+9.7%

Gross profit$243.3M+8.6%

Operating income-$4.6M-124%

Net income$3.6M-80.8%

EPS (diluted)$0.02-81.8%

Balance sheet

See full

Cash & equivalents$282.2M+29.6%

Total debt$50.8M-9.3%

Total equity$1.2B+63.1%

Total assets$1.6B+41.8%

Cash flow

See full

Operating cash flow$34.0M+67.2%

CapEx$5.2M—

Free cash flow$28.8M+41.6%

Valuation & ratios

Valuation

See full

Market cap$4.35B+10.4%

Enterprise value$4.12B+14.7%

P/E11.6×-5.5×

P/S4×+0.3×

Profitability

See full

Gross margin91.5%-0.6pp

Operating margin7.4%-16.2pp

Net margin34.3%+11.3pp

Returns & leverage

See full

Return on equity37.3%+0.1pp

Debt / equity0×0.0×

Current ratio3.6×+0.7×

Segments

By product

See full

Nuplazid$166.9M+4.5%

Daybue$101.1M+19.6%

By segment

See full

Reportable Segment Aggregation Before Other Operating$268.1M+9.7%

Competitors

By market cap

Biogen$29.5B+56.0%

Neurocrine Biosciences$17.7B+34.0%

Acadia Pharmaceuticals$4.3B+14.8%

LBR

LB Pharmaceuticals Inc Common Stock$997.4M—

Zevra Therapeutics, Inc.$574.0M-2.9%

Prothena Corporation plc$455.5M+23.2%

Minerva Neurosciences$195.9M+1,234%

Polaryx Therapeutics, Inc. $97.7M—

By revenue growth

Zevra Therapeutics, Inc.+201%

Neurocrine Biosciences+28.6%

Acadia Pharmaceuticals+9.9%

Biogen+0.3%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Acadia Pharmaceuticals34.3%+11.3pp

Neurocrine Biosciences21.55%+8.9pp

Biogen8.81%-6.5pp

Profile

Acadia Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological and rare diseases. The company focuses on addressing significant unmet medical needs through a portfolio of first-in-class treatments and a pipeline of late-stage clinical candidates.

Competitive position

Acadia holds a first-mover advantage in Parkinson’s disease psychosis and Rett syndrome with the only FDA-approved therapies for these specific indications.

GeographiesUnited States, Switzerland

Customer segmentsPatients, Healthcare Providers, Specialty Distributors

Business modelResearch and Development, Product Sales

SuppliersContract manufacturing organizations, Clinical research organizations, Scientific research institutions

CustomersSpecialty pharmacies, Wholesale distributors, Hospitals, Long-term care facilities

CountryUnited States of America

Listed2004

Employees610.0

CEOCatherine E. Owen Adams

SectorHealthcare

IndustryBiotechnology

Websiteacadia.com

FilingsSEC EDGAR

Ask your AI about Acadia Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Acadia Pharmaceuticals's market cap?: Acadia Pharmaceuticals (ACAD) has a market capitalization of $4.3B and trades on NASDAQ.
What is Acadia Pharmaceuticals's revenue and profitability?: Acadia Pharmaceuticals generated $1.1B in trailing twelve-month revenue with net income of $375.7M, representing a net margin of 34.3%. Gross margin stands at 91.5%, with free cash flow of $186.7M. These figures are based on the Q1 2026 filing.
Who are Acadia Pharmaceuticals's competitors?: Acadia Pharmaceuticals's key competitors include Neurocrine Biosciences, Biogen, Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Where is Acadia Pharmaceuticals headquartered?: Acadia Pharmaceuticals is headquartered in United States of America and employs approximately 610 people. It has been publicly traded since 2004.